Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

70.56
+1.021.47%
Pre-market: 70.30-0.2600-0.37%05:28 EDT
Volume:691.02K
Turnover:48.59M
Market Cap:5.89B
PE:-115.67
High:70.84
Open:69.42
Low:69.05
Close:69.54
52wk High:90.87
52wk Low:49.38
Shares:83.46M
Float Shares:77.19M
Volume Ratio:1.00
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-35.61
PE(LYR):9.07

Loading ...

PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says

MT Newswires Live
·
Jul 27

Earning Preview: PTC Therapeutics Q2 revenue is expected to increase by 74.33%, and institutional views are mostly bullish

Earnings Agent
·
Jul 24

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

THOMSON REUTERS
·
Jul 23

Barclays Remains a Buy on PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Personalis (PSNL) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 20

PTC Therapeutics is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 20

PTC Therapeutics price target lowered to $93 from $95 at Wells Fargo

TIPRANKS
·
Jul 20

PTC Therapeutics Schedules Second-quarter 2026 Results Webcast Conference Call

Reuters
·
Jul 16

PTC Therapeutics is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 16

PTC Therapeutics price target raised to $130 from $124 at Cantor Fitzgerald

TIPRANKS
·
Jul 16

PTC Therapeutics price target raised to $95 from $93 at BofA

TIPRANKS
·
Jul 15

U.S. Research Roundup-equinix, Goldman Sachs, Jpmorgan

Reuters
·
Jul 15

PTC Therapeutics Director Mary L. Smith Disposes of USD 1.43 Million in Common Shares

Reuters
·
Jul 14

PTC Therapeutics EVP, CLO Mark Elliott Boulding Disposes of Common Shares Worth $257,864.88

Reuters
·
Jul 09

Barclays Remains a Buy on PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 08

PTC Therapeutics is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 07

RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Does Triple Russell 2000 Defensive Index Inclusion Reframe PTC Therapeutics’ Risk Profile And Rare-Disease Story (PTCT)?

Simply Wall St.
·
Jul 07

PTC Therapeutics Chief Technical Ops Officer Neil Gregory Almstead Disposes of 8,130 Common Shares Worth $692,193.06

Reuters
·
Jul 01

PTC Therapeutics Chief Technical Ops Officer Neil Gregory Almstead Sells USD 3.32 Million in Common Shares

Reuters
·
Jun 27